RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 CARE-MS I Follow-up: Alemtuzumab Efficacy, Safety for MS Treatment Maintained for More than 4 Years
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 11
OP 12
DO 10.1177/155989771429008
UL http://mdc.sagepub.com/content/14/29/11.abstract
AB An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab [NCT00930553; Coles AJ et al. ECTRIMS 2014 (poster P090)], a follow-up to the phase 3, randomized, head-to-head CARE-MS I study [NCT00530348], has demonstrated the continuing efficacy and safety of subcutaneous alemtuzumab in treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) who were treated for up to 4 years.